Brain imaging for psychiatrists, Part 2: Structural (static) measures

Both MRI (= magnetic resonance imaging) and PET (=positron emission tomography) can be used to measure fixed elements of brain function.

Fig 1.
MRI scans reveal brain damage from alcohol

Source: David Nutt, Imperial College London.

MRI can give detailed measurements of brain morphometry as used for instance in radiological diagnosis. A clear example of this is shown in Fig 1 which demonstrates the massive loss of brain tissue in four patients with alcohol dependence as compared with an age and sex matched healthy control group (image courtesy Prof David Nutt, Imperial College London). Similar brain shrinkage is shown in dementias such as Alzheimer's disease as seen in Fig 2.

These morphometric measures can be made quantitative through statistical programmes such as VBM [voxel-based morphometry] that can estimate the density of the brain and its subregions. However, DTI imaging can be used to delineate neuronal pathways across the brain [see part 1] and this is now becoming more quantitative with statistical procedures developing so that different patient populations can be compared.

Fig 2. MRI scans reveal brain shrinkage in Alzheimer's disease patients

Source: David Nutt, Imperial College London.

PETand SPECT(=single photon emission computerized tomography) can measure the distribution and density of proteins to which tracers bind.

Example of the evaluation of the receptors distribution: Fig 3 shows a PET scan of dopamine D2 receptors in brain as identified by the binding of 11C-raclopride. Many of these dopamine D2 receptors are detected in the striatum which makes sense as dopamine-producing cell bodies are located in this region1. In contrast the GABA-A receptors have a very different distribution2 as seen in fig 4 which shows a PET scan of the benzodiazepine receptor tracer 11C-flumazenil. These are largely detected in cortex with relatively little binding seen in striatum and thalamus.

Fig 3. Multiple PET tracers for the dopamine system

Source: David Nutt, Imperial College London.

Fig 4.
PET scan measuring GABA-A receptors in normal brain and in people with panic disorder

Source: David Nutt, Imperial College London.

Measuring receptor density with PET and SPECT has proved very useful in defining alterations of neurotransmitter receptors in disease states.

Example of the evaluation of receptor density: Fig 3d shows the reduction in number of D2 receptors in patients with cocaine addiction, which is believed to contribute to the inability of those with cocaine abuse to restrain their drug use3. In the right sided image in Fig 4 we can see reduced benzodiazepine/GABA-A receptors in fronto/temporal brain regions in patients with panic disorder. Similar benzodiazepine/GABA-A receptor deficits are also found, though to a lesser extent in patients with Generalized Anxiety Disorder and Post Traumatic Stress Disorder, as well as in epileptic foci. It is thought that the reduction in GABA-A receptors leads to reduced GABA-A inhibition which in turn leads to excessive glutamate excitation that ultimately provokes seizures depending on the brain regions affected4.

PET tracers now exist to measure a number of neurotransmitter receptors and reuptake sites and a few enzymes. One of the most revealing studies has been those estimating the density of the serotonin 5-HT1A receptor in depression. These data are shown in fig 5 using the 3 axis projection system. The voxels that show a significant reduction in density in depressed patients as compared with age- and sex-matched healthy controls are shown in shades of grey with the darker the colour the more significant the reduction. This was the first demonstration of a serotonin deficit in living human brain in depression and was further extended by the same group revealing that the deficit did not recover on successful treatment. This suggests that the reduced serotonin receptor number may be a trait – rather than a state – marker of depression5. We hypothesize that the effect of SSRIs to lift depression is due to their increasing synaptic 5-HT concentrations so a level that offsets or compensates for the receptor deficiency. Also first-degree relatives of the depressed subjects had a similar though lesser reductions on receptor number which suggests this possibly has a genetic basis.

Fig 5.
Density of the serotonin 5-HT1A receptor in depression

Source: David Nutt, Imperial College London.

PET tracers can also be used to measure enzyme distribution and potential activity for example the evaluation of the enzyme distribution and activity. The well studied brain dopamine system is thought to play a central role in drug abuse. We can now measure most of the elements of this neurotransmitter system as shown in fig 3. 18F-dopa can be used to give an estimate of dopamine synthesis rate, 11C-deprenyl to measure MAO activity, 11C-raclopride to measure D2 receptors and 11C-bCIT to measure serotonin transporter density.

While the use of neuroimaging has helped us better understand alterations in the brain dopamine system in addiction, it has also proved useful in aiding diagnosis of Parkinson's disease where 18F-dopa uptake into the striatum is reduced6. Also the 11C-deprenyl tracer has been used to reveal that cigarette smoking blocks this enzyme which may explain the mood elevating effects of smoking (Fig 3a).

Measures of the density of proteins can be useful in diagnosis as shown in Alzheimer's disease where the deposits of b-amyloid can be imaged using a tracer such as 11C-PIB as in the right side of fig 6. The left side of this figure shows the other imaging technique (18F-FDG PET) which is used in diagnosis by measuring cerebral metabolic rates of glucose.

 

Fig 6. 18F-FDG PET measures cerebral metabolic rates of glucose and 11C-PIB PET measures the density of b-amyloid deposits

Source: David Nutt, Imperial College London.

Fig 7.
Using 11C-raclopride PET to estimate receptor occupation of D2 receptor antagonist

Source: David Nutt, Imperial College London.

Left: Before treatment, Right: After treatment

Drug- receptor occupation studies

Due to the breakthrough advances in imaging techniques, it is now possible noninvasively measure binding of drugs to their target receptors. For a range of drugs used in neurology and psychiatry we can now perform a form of dose-response measurement at the precise target site of drug action, a big improvement as previously we had to make estimates of brain target engagement from plasma concentration measurements. In fig 7, this is shown for a D2 receptor antagonist. Both scans use 11C-raclopride to estimate the number of dopamine D2 receptors available for the tracer to bind to. In the untreated state a high level of 11C-raclopride binding is seen in the dopamine rich striatal regions. However after treatment with a D2 receptor antagonist neuroleptic this is dramatically reduced because the drug competes with 11C-raclopride for the same binding site.

Studies such as these were instrumental in changing the dosing regimens of dopamine blocking drugs for psychosis because they revealed several important facts. First the receptor occupation needed to produce an antipsychotic effect was about 65%. But when occupation reached over 80% then adverse effects such as extra-pyramidal symptoms and elevated prolactin concentrations were seen. This means that the therapeutic window for these drugs is very narrow7. Even a small increase in dose can switch a patient from being underdosed [i.e. occupation < 65% ] to overdosed [i.e. occupation > 80%].

The second advance was that it became apparent that certain doses of D2 receptor antagonist produced saturation of the dopamine receptors. Thus there was no added clinical benefit when D2 receptor occupancy was high, and when striatial receptor occupancy was lowered, the safety and tolerability profile of drugs improved.

Imaging of the serotonin reuptake site has shown rather different results because here it is necessary to get over 70-80% occupation by a reuptake blocker to produce significant lifting of depression8. Different receptor occupation/effect relationships apply to different drugs so the full mu receptor opioid agonist produces it actions with very low [less than 8%] occupation of the receptor whereas the partial mu receptor opioid agonist requires occupation of > 50% of receptors9.

Conclusion

PET and MRI imaging offer important new ways to explore brain structure and function in psychiatry and neurology. At present whilst MRI is in regular clinical use for diagnosis, PET is largely just a research tool, but some tracers e.g. F-DOPA and 11C-PIB are being used to aid diagnosis of Parkinson's disease and Alzheimer's disease respectively. The future development of tracers that use 18F instead of 11C will further spread the availability of these in clinical practice. This is because the much longer half-life of 18F [110 min v 20min] allows production of the radioactive tracer at a central cyclotron site with distribution to multiple hospitals that have PET scanners. In contrast 11C tracers have to be made on the same site as the scanner, so each site needs its own cyclotron.

References
  1. Hall H, et al. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994 Dec;11(4):245-56.
  2. Nutt D. GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med. 2006 Apr 15;2(2):S7-11
  3. Volkow et al. Decreased Dopamine D, Receptor Availability Is Associated With Reduced Frontal Metabolism in Cocaine Abusers. Synapse 1993;14:169-177.
  4. Kim YS, Yoon BE. Altered GABAergic Signaling in Brain Disease at Various Stages of Life. Exp Neurobiol. 2017 Jun; 26(3): 122–131.
  5. Carhatt-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017 Sep; 31(9): 1091–1120.
  6. Asenbaum S, et al.  Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease.  J Nucl Med. 1997 Feb;38:1-6
  7. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011 Apr;17(2):97-103.
  8. Meyer JH, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004 May;161(5):826-35.
  9. Nelson LS, Olsen D. Opioids. In: Hoffman RS, Howland M, Lewin NA, Nelson LS, Goldfrank LR. eds. Goldfrank's Toxicologic Emergencies. 10th ed. New York, NY: McGraw-Hill; 2015.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country